Cargando…

Development of CDK4/6 Inhibitors: A Five Years Update

The inhibition of cyclin dependent kinases 4 and 6 plays a role in aromatase inhibitor resistant metastatic breast cancer. Three dual CDK4/6 inhibitors have been approved for the breast cancer treatment that, in combination with the endocrine therapy, dramatically improved the survival outcomes both...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ammazzalorso, Alessandra, Agamennone, Mariangela, De Filippis, Barbara, Fantacuzzi, Marialuigia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967197/ https://www.ncbi.nlm.nih.gov/pubmed/33803309 http://dx.doi.org/10.3390/molecules26051488

Ejemplares similares

Anticancer Inhibitors
por: Ammazzalorso, Alessandra, et al.
Publicado: (2022)

Anticancer Activity of Natural Products and Related Compounds
por: De Filippis, Barbara, et al.
Publicado: (2023)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
por: Maccallini, Cristina, et al.
Publicado: (2022)

Resveratrol Analogues as Dual Inhibitors of Monoamine Oxidase B and Carbonic Anhydrase VII: A New Multi-Target Combination for Neurodegenerative Diseases?
por: Carradori, Simone, et al.
Publicado: (2022)

PPAR Ligands Induce Antiviral Effects Targeting Perturbed Lipid Metabolism during SARS-CoV-2, HCV, and HCMV Infection
por: Fantacuzzi, Marialuigia, et al.
Publicado: (2022)

Benzothiazole Derivatives Endowed with Antiproliferative Activity in Paraganglioma and Pancreatic Cancer Cells: Structure–Activity Relationship Studies and Target Prediction Analysis
por: Amoroso, Rosa, et al.
Publicado: (2022)

The Selective Acetamidine-Based iNOS Inhibitor CM544 Reduces Glioma Cell Proliferation by Enhancing PARP-1 Cleavage In Vitro
por: Gallorini, Marialucia, et al.
Publicado: (2019)

Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies
por: Ammazzalorso, Alessandra, et al.
Publicado: (2016)

Coumarin-Based Dual Inhibitors of Human Carbonic Anhydrases and Monoamine Oxidases Featuring Amino Acyl and (Pseudo)-Dipeptidyl Appendages: In Vitro and Computational Studies
por: Agamennone, Mariangela, et al.
Publicado: (2022)

Design, Synthesis and Biological Evaluation of Aromatase Inhibitors Based on Sulfonates and Sulfonamides of Resveratrol
por: Fantacuzzi, Marialuigia, et al.
Publicado: (2021)

Fibrate-based N-acylsulphonamides targeting carbonic anhydrases: synthesis, biochemical evaluation, and docking studies
por: Ammazzalorso, Alessandra, et al.
Publicado: (2019)

Antiviral Peptides as Anti-Influenza Agents
por: Agamennone, Mariangela, et al.
Publicado: (2022)

New azolyl-derivatives as multitargeting agents against breast cancer and fungal infections: synthesis, biological evaluation and docking study
por: Maccallini, Cristina, et al.
Publicado: (2021)

Benzenesulfonamide derivatives as Vibrio cholerae carbonic anhydrases inhibitors: a computational-aided insight in the structural rigidity-activity relationships
por: Fantacuzzi, Marialuigia, et al.
Publicado: (2023)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies
por: Ammazzalorso, Alessandra, et al.
Publicado: (2020)

The Development of BTK Inhibitors: A Five-Year Update
por: Tasso, Bruno, et al.
Publicado: (2021)

The Development of FAK Inhibitors: A Five-Year Update
por: Spallarossa, Andrea, et al.
Publicado: (2022)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2019)

A Novel Prodrug of a nNOS Inhibitor with Improved Pharmacokinetic Potential
por: Maccallini, Cristina, et al.
Publicado: (2020)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
por: Rampioni Vinciguerra, Gian Luca, et al.
Publicado: (2022)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
por: Garutti, Mattia, et al.
Publicado: (2021)

CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
por: Arsenijevic, Tatjana, et al.
Publicado: (2023)

CDK4/6 inhibitor resistance: A bibliometric analysis
por: Pang, Jiayuecheng, et al.
Publicado: (2022)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
por: Piezzo, Michela, et al.
Publicado: (2020)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

An Integrated Computational Approach to Rationalize the Activity of Non-Zinc-Binding MMP-2 Inhibitors
por: Di Pizio, Antonella, et al.
Publicado: (2012)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Liu, Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n58bf81qbqes9h8u8ik029b6vq